DDInter1627 DDInter53
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rufinamide {u} (Compound) binds {v} (Gene) SCN8A
SCN8A {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rufinamide {u} (Compound) causes {v} (Side Effect) Balance disorder
Balance disorder {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Alpelisib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rufinamide (Compound) binds SCN8A (Gene) and SCN8A (Gene) is bound by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Alpelisib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rufinamide (Compound) causes Balance disorder (Side Effect) and Balance disorder (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Alpelisib